Abstract 1502
Background
Overall survival (OS) is the most relevant endpoint for evaluation of checkpoint inhibitors (CPI). Identification of early surrogates of OS is important to inform early clinical efficacy signals and treatment decisions. Here, we evaluated multiple metrics of circulating tumor DNA (ctDNA) for association with OS in the Ph3 OAK study, which demonstrated clinically significant OS benefit in ≥ 2L NSCLC patients treated with atezolizumab vs docetaxel.
Methods
Plasma from 94 patients taken at baseline and at subsequent cycles of therapy every three weeks (C2D1, C3D1, and C4D1) were analyzed retrospectively for ctDNA with the AVENIO ctDNA Surveillance Kit* (Jiang et al., 2018). Mutations detected in matched PBMC DNA were excluded in correlation analyses with clinical outcomes (Yaung et al., 2019). ctDNA was measured by allele frequency (AF) or mutant molecules per milliliter (MMPM), and summarized across multiple mutations within a sample by median, mean or maximum. Concordance between these per-sample metrics and PFS/OS were assessed using C index, which is equivalent to AUC under a Receiver Operating Characteristic (ROC) curve. *For Research Use Only; Not for use in diagnostic procedures.
Results
Using absolute and relative change from baseline of these metrics showed various levels of association with OS for both treatment arms (atezolizumab arm C index average 0.63, range 0.47 -0.76 and docetaxel arm C index average 0.50, range 0.39 - 0.61). As noted, maximal MMPM at C3D1 or 6 weeks had comparable association with OS in both treatment arms (atezolizumab arm C index = 0.74 and docetaxel arm C index = 0.73). Dichotomized at a median of 8.75 maximal MMPM, KM curves showed the 1-year survival rate in the atezolizumab arm among MMPM low vs high patients was 0.81 vs 0.43; and in the docetaxel arm was 0.7 vs 0.07. Associations with PFS tended to be weaker than those for OS.
Conclusions
Overall ctDNA levels were associated with OS in 2L+ NSCLC. ctDNA may be a promising non-invasive blood based biomarker in the metastatic setting of NSCLC and warrants further studies to demonstrate its utility in clinical development.
Clinical trial identification
OAK (NCT02008227).
Editorial acknowledgement
Legal entity responsible for the study
Roche.
Funding
Roche.
Disclosure
D.R. Gandara: Advisory / Consultancy: AstraZeneca, Celgene, CellMax Life, FujiFilm, Roche-Genentech, Guardant Health, Inviata, IO Biotech, Lilly, Liquid Genomics, Merck, Samsung Bioepis, Pfizer; Research grant / Funding (institution), Research grants : Bristol-Myers Squib, Roche-Genentech, Novartis, Merck. W. Zou: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. J. Jiang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. S. Yaung: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. F. Fuhlbrück: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. J. Wu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. M. Peterson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. J. Palma: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. M. Ballinger: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. E. Peters: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. D. Shames: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. N. Patil: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche.
Resources from the same session
3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Presenter: Francesca Zannier
Session: Poster Display session 1
Resources:
Abstract
2433 - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
Presenter: Cheol-Hee Shin
Session: Poster Display session 1
Resources:
Abstract
2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation
Presenter: Antonin Levy
Session: Poster Display session 1
Resources:
Abstract
3213 - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor
Presenter: Alexey Bogdanov
Session: Poster Display session 1
Resources:
Abstract
3722 - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.
Presenter: Sungwon Shin
Session: Poster Display session 1
Resources:
Abstract
5805 - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging Guided Cancer Photothermal Therapy
Presenter: sheng wang
Session: Poster Display session 1
Resources:
Abstract
5251 - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Presenter: Ivan Zaporozhchenko
Session: Poster Display session 1
Resources:
Abstract
3657 - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes
Presenter: Bianca Cabral
Session: Poster Display session 1
Resources:
Abstract
2839 - Obesity and prognosis in breast cancer
Presenter: Noha Ibrahim
Session: Poster Display session 1
Resources:
Abstract
5132 - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells
Presenter: Chang Liu
Session: Poster Display session 1
Resources:
Abstract